An update from Simulations Plus ( (SLP) ) is now available.
On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025, which ended on February 28, 2025. The company experienced a 23% increase in total revenue, reaching $22.4 million, with software revenue rising by 16% and services revenue by 34%. Despite a decrease in net income and diluted EPS compared to the previous year, the company maintained its full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20. The strong performance was driven by significant growth in its Quantitative Systems Pharmacology business unit and robust services revenue, particularly in Medical Communications. Simulations Plus is optimistic about maintaining its momentum into the second half of 2025, despite challenges in the biopharma funding environment.
More about Simulations Plus
Simulations Plus, Inc. is a leading provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Their comprehensive biosimulation solutions integrate AI/ML, physiologically based pharmacokinetics, biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. The company also provides simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development, serving clients globally for over 25 years.
YTD Price Performance: -11.25%
Average Trading Volume: 225,968
Technical Sentiment Signal: Strong Buy
Current Market Cap: $484.2M
For detailed information about SLP stock, go to TipRanks’ Stock Analysis page.